ANAB icon

AnaptysBio

34.40 USD
+0.11
0.32%
At close Updated Oct 16, 4:00 PM EDT
Pre-market
After hours
34.40
0.00
0%
1 day
0.32%
5 days
7.3%
1 month
77.32%
3 months
28.07%
6 months
80.48%
Year to date
157.49%
1 year
-0.84%
5 years
42.86%
10 years
102.35%
 

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 136

0
Funds holding %
of 7,495 funds
0
Analysts bullish %
of 6 analysts
0
Positive news %
of 6 articles
Price charts implemented using Lightweight Charts™